Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small molecule inhibitors
110(33):13594-9
GSK256066 (10 μg/kg) is administered intratracheally at different times (2
selective and cell permeable inhibitor of the homologous protein lysine methyltransferases
3-3 μM) dose-dependently reduces the migration of cells induced by growth factors (PDGF-BB
Tivantinib previr Evidence that PERK is implicatedTivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c Met with potential antineoplastic activity. c Met inhibitor ARQ 197 binds to the c Met protein and disrupts c Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c Met protein or expressing consitutively activated c Met protein. c Met protein, the product of the proto oncogene c Met, is a receptor tyrosine kinase also known as
US$ 356.00
US$ 182.00
US$ 220.00
US$ 198.50
US$ 275.00
US$ 61.00